Recombinant human interferon-γ modulates Rift Valley fever virus infection in the rhesus monkey

J. C. Morrill, C. W. Czarniecki, C. J. Peters

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Prophylactic treatment of rhesus macaques with 104-106 U/kg of recombinant human interferon-γ (rHuIFN-γ) modulated Rift Valley fever (RVF) virus infection. IFN was given intramuscularly at 24 h prior to infection and daily thereafter for a total of five doses. After infection, treated monkeys showed no evidence of clinical disease; some had no detectable viremia; when viremia was observed, peak virus titers were decreased compared to control infected monkeys; and only minor and transient perturbations in hematologic and clinical chemistry values were seen. Untreated infected control monkeys developed high-titered viremia, mild to severe clinical disease, and moderate to severe changes in hemostatic parameters and clinical laboratory measurements. No evidence of synergism was noted when RVF virus-infected monkeys were treated prophylactically with combined low doses of rHuIFN-γ and rHuIFN-αA.

Original languageEnglish (US)
Pages (from-to)297-304
Number of pages8
JournalJournal of Interferon Research
Volume11
Issue number5
StatePublished - 1991
Externally publishedYes

Fingerprint

Rift Valley fever virus
Virus Diseases
Macaca mulatta
Interferons
Haplorhini
Viremia
Clinical Chemistry
Hemostatics
Infection
Viral Load

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Recombinant human interferon-γ modulates Rift Valley fever virus infection in the rhesus monkey. / Morrill, J. C.; Czarniecki, C. W.; Peters, C. J.

In: Journal of Interferon Research, Vol. 11, No. 5, 1991, p. 297-304.

Research output: Contribution to journalArticle

Morrill, J. C. ; Czarniecki, C. W. ; Peters, C. J. / Recombinant human interferon-γ modulates Rift Valley fever virus infection in the rhesus monkey. In: Journal of Interferon Research. 1991 ; Vol. 11, No. 5. pp. 297-304.
@article{5cae31a3baeb40cf882618ed43332e5c,
title = "Recombinant human interferon-γ modulates Rift Valley fever virus infection in the rhesus monkey",
abstract = "Prophylactic treatment of rhesus macaques with 104-106 U/kg of recombinant human interferon-γ (rHuIFN-γ) modulated Rift Valley fever (RVF) virus infection. IFN was given intramuscularly at 24 h prior to infection and daily thereafter for a total of five doses. After infection, treated monkeys showed no evidence of clinical disease; some had no detectable viremia; when viremia was observed, peak virus titers were decreased compared to control infected monkeys; and only minor and transient perturbations in hematologic and clinical chemistry values were seen. Untreated infected control monkeys developed high-titered viremia, mild to severe clinical disease, and moderate to severe changes in hemostatic parameters and clinical laboratory measurements. No evidence of synergism was noted when RVF virus-infected monkeys were treated prophylactically with combined low doses of rHuIFN-γ and rHuIFN-αA.",
author = "Morrill, {J. C.} and Czarniecki, {C. W.} and Peters, {C. J.}",
year = "1991",
language = "English (US)",
volume = "11",
pages = "297--304",
journal = "Journal of Interferon Research",
issn = "0197-8357",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Recombinant human interferon-γ modulates Rift Valley fever virus infection in the rhesus monkey

AU - Morrill, J. C.

AU - Czarniecki, C. W.

AU - Peters, C. J.

PY - 1991

Y1 - 1991

N2 - Prophylactic treatment of rhesus macaques with 104-106 U/kg of recombinant human interferon-γ (rHuIFN-γ) modulated Rift Valley fever (RVF) virus infection. IFN was given intramuscularly at 24 h prior to infection and daily thereafter for a total of five doses. After infection, treated monkeys showed no evidence of clinical disease; some had no detectable viremia; when viremia was observed, peak virus titers were decreased compared to control infected monkeys; and only minor and transient perturbations in hematologic and clinical chemistry values were seen. Untreated infected control monkeys developed high-titered viremia, mild to severe clinical disease, and moderate to severe changes in hemostatic parameters and clinical laboratory measurements. No evidence of synergism was noted when RVF virus-infected monkeys were treated prophylactically with combined low doses of rHuIFN-γ and rHuIFN-αA.

AB - Prophylactic treatment of rhesus macaques with 104-106 U/kg of recombinant human interferon-γ (rHuIFN-γ) modulated Rift Valley fever (RVF) virus infection. IFN was given intramuscularly at 24 h prior to infection and daily thereafter for a total of five doses. After infection, treated monkeys showed no evidence of clinical disease; some had no detectable viremia; when viremia was observed, peak virus titers were decreased compared to control infected monkeys; and only minor and transient perturbations in hematologic and clinical chemistry values were seen. Untreated infected control monkeys developed high-titered viremia, mild to severe clinical disease, and moderate to severe changes in hemostatic parameters and clinical laboratory measurements. No evidence of synergism was noted when RVF virus-infected monkeys were treated prophylactically with combined low doses of rHuIFN-γ and rHuIFN-αA.

UR - http://www.scopus.com/inward/record.url?scp=0026388872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026388872&partnerID=8YFLogxK

M3 - Article

C2 - 1774469

AN - SCOPUS:0026388872

VL - 11

SP - 297

EP - 304

JO - Journal of Interferon Research

JF - Journal of Interferon Research

SN - 0197-8357

IS - 5

ER -